A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

428 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-13

Study Completion Date

2024-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

PRF-110 is a viscous, yellowish clear oily solution of ropivacaine intended for administration into surgical sites to provide post-operative analgesia. The pharmacokinetic profile for PRF-110 suggests that its effect could last up to 72 hours. This is A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study to Evaluate the Analgesic Efficacy and Safety of Intra-operative Administration of PRF-110 Following Unilateral Bunionectomy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of PRF110 in Bunionectomy Surgery

NCT02784327

Post Operative Pain

UNKNOWN PHASE2

Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures

NCT02499575

Bunion Hallux Rigidus

TERMINATED NA

Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery

NCT03111186

Carpal Tunnel Syndrome Dupuytren Contracture Trigger Digit +2 more

COMPLETED PHASE2

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

NCT07222748

Postoperative Pain

RECRUITING PHASE3

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

NCT01710345

Acute Pain

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRF-110 is a unique, sustained-release, oil-based solution formulation of ropivacaine intended for administration into surgical sites for the prevention of postoperative pain. The formulation is designed to have an effect for up to 72 hours. It is postulated that PRF-110 will improve postoperative pain management by providing prolonged pain relief at the surgical site; thereby, reducing the amount of systemic analgesia needed after surgery. The slow, local release of ropivacaine following administration of PRF-110 has been demonstrated in dissolution studies, in postoperative pain studies in animals, in an experimental pain study in human volunteers, and in an open-label Phase 2 hernia repair trial to result in very low plasma concentrations of drug, therefore reducing the probability of systemic adverse events. This is a randomized, double-blind study to evaluate the efficacy and safety of PRF-110 compared with saline placebo and with ropivacaine hydrochloride injection administered intraoperatively in subjects undergoing unilateral bunionectomy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bunion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study is a randomized, double-blind, placebo and active-controlled study.

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Before the start of the study, a computer-generated randomization schedule will be prepared for each site. The randomization codes will be stored in a secured area. Uniquely numbered study medication kits will be assigned to subjects according to the randomization codes.

Randomization will take place on the day of surgery (Day 1) after performance of baseline assessments. Subjects who continue to meet eligibility criteria will be randomized in a 2:2:1 ratio to 1 of the 3 treatment groups:

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRF-110

PRF-110 3.6% ropivacaine, to be applied into the surgical wound

Group Type EXPERIMENTAL

Ropivacaine

Intervention Type DRUG

A long acting formulation of ropivacaine

Saline .9%

Saline .9%, to b be applied into the surgical wound

Group Type PLACEBO_COMPARATOR

Ropivacaine

Intervention Type DRUG

A long acting formulation of ropivacaine

Ropivacaine

Ropivacaine Hydrochloride 0.5%, up to 10 mL, to be applied into the surgical site

Group Type ACTIVE_COMPARATOR

Ropivacaine

Intervention Type DRUG

A long acting formulation of ropivacaine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ropivacaine

A long acting formulation of ropivacaine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects must meet all of the following criteria to be eligible for inclusion into the study:

1. Able to provide written informed consent prior to any study procedures.
2. Able to communicate clearly with the Investigators and study staff.
3. Males and females aged 18 years or older.
4. Scheduled for elective primary unilateral first metatarsal bunionectomy surgery (osteotomy and internal fixation) with no ancillary procedures.
5. Female subjects must be surgically sterile; or at least 2 years postmenopausal; or have a monogamous partner who is surgically sterile; or practicing doublebarrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than two months prior to screening and commit to the use of an acceptable form of birth control for the duration of the study and for 30 days after completion of the study.
6. Negative alcohol breath/saliva test and urine drug screen for drugs of abuse at Screening and at Baseline. Subjects with positive results on the alcohol breath/saliva test or urine drug screen at Screening, and/or prior to surgery, will not be allowed to proceed in the study unless the results can be explained by a current prescription or acceptable over-the-counter medication as determined by the Investigator. Note that for those subjects who test positive for tetrahydrocannabinol (THC), if they are willing to abstain from use or consumption of THC-containing products from Screening thru last Follow-up Visit, they may be allowed to participate in the study.
7. American Society of Anesthesiologists (ASA) Physical Status of I or II (see Appendix, Section 14.1).
8. Body Mass Index (BMI) ≤35.

Exclusion Criteria

subject will be excluded from the study if any of the following criteria are met:

1. Has clinically significant allergies to an opioid, unless has subsequently tolerated other opioids and, in the opinion of the Investigator, could tolerate a rescue drug containing oxycodone.
2. Has a known or suspected allergy to any local anesthetic or to acetaminophen.
3. Has a known or suspected history of alcohol, opiate or other drug abuse or dependence within 12 months prior to screening.
4. Is unable to refrain from alcohol consumption for a period beginning 24 hours prior to surgery through the end of the 72 -hour evaluation period.
5. Has taken any analgesic or non-opioid pain medication other than acetaminophen (e.g., NSAIDs, cyclooxygenase-2 \[COX 2\] inhibitors) within 12 hours prior to surgery or any aspirin-containing product within 7 days of the Baseline assessments. Aspirin up to 325 mg once daily for cardiovascular prophylaxis is allowed.
6. Has taken any opioid analgesics or used systemic steroids within 4 days of surgery.
7. Has been using opiates or any non-steroidal anti-inflammatory drug chronically (more than 10 consecutive days) anytime over the past 3 months.
8. Has used antipsychotics or antiepileptics within 30 days prior to surgery. Use of sedatives, hypnotics, antianxiety agents, and antidepressants (other than monoamine oxidase inhibitors \[MAOIs\]) are allowed if being used for a nonpain indication and at a stable dose within the previous 30 days.
9. Has history of or positive test results for HIV or hepatitis B or C at Screening.
10. Has any history of epilepsy, other than childhood febrile seizures, before the age of 6.
11. Has any history of psychosis, current clinically significant symptomatic psychiatric disorder, or a history of suicide attempt in the past 10 years.
12. Has taken herbal agents or nutraceuticals (e.g., chapparal, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) during any of the 7 days prior to surgery that could potentially confound the analgesic response in the Investigator's opinion.
13. Has transaminase levels \> 2 x ULN, or bilirubin level \> 1.5 x ULN (unless Gilbert's syndrome), or estimated glomerular filtration rate (eGFR) \< 60 mL/min. Has poorly controlled diabetes with hemoglobin A1c \>7.5%.

15\. Has any clinically significant condition including an acute or chronic painful physical restrictive condition or any other significant laboratory abnormality that would, in the opinion of the Investigator, confound study assessments or adversely affect subject safety. 16. Has received another investigational drug within 30 days of scheduled surgery.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No